The main purpose of this study is to learn if adding a drug called bevacizumab to treatment with two chemotherapy drugs for early stage HER2-negative breast cancer will prevent breast cancer from returning.
Bevacizumab is considered investigational because it is still being researched and has not received approval from the U.S. Food and Drug Administration (FDA) for use in treating early stage breast cancer. Bevacizumab is called a targeted therapy because it works by blocking a protein called vascular endothelial growth factor (VEGF) that helps new blood vessels form. Without new blood vessels, the growth of the tumor is slowed.
Two of the chemotherapy drugs used in this study are docetaxel and cyclophosphamide. These drugs are used in standard combinations of chemotherapy for breast cancer.